Skip to main content
Have a personal or library account? Click to login
Is there a correlation between signal intensity ratio of 3T MRI and molecular subtypes of breast cancer? Cover

Is there a correlation between signal intensity ratio of 3T MRI and molecular subtypes of breast cancer?

Open Access
|Jul 2026

Figures & Tables

FIGURE 1.

Inclusion and exclusion criteria and the data collection flowchart showing the study population.

FIGURE 2.

MR images of a 48 years-old patient diagnosed with luminal B subtype breast cancer. T1 weight image (A), T2 fatsuppression sequence image (B), DWI image (C) and ADC map (D) was shown. T1 and T2 signal intensity ratio (A and B) were calculated by proportioning the average signal intensity of the lesion (red circle) to the average signal intensity of the pectoral muscle (yellow circle). Red arrows show the lesions and yellow arrows show the pectoral muscles. ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging

FIGURE 3.

The comparison of receiver operating characteristic (ROC) curve of single and combined parameters for distinguishing one subtype from all other subtypes. ADC = apparent diffusion coefficient; ALNM = axillary lymph node metastasis; TN: triple-negative; T1 SIR = T1 signal intensity ratio; T2 SIR = T2 signal intensity ratio

MRI quantitative parameters for molecular subtypes of breast cancer

ParametersLuminal A (n = 52)Luminal B (n = 135)HER2-enriched (n = 31)TNBC (n = 45)p
T1 SIR1.318 (1.179–1.630)1.366 (1.209–1.620)1.515 (1.268–1.788)1.254 (1.141–1.401)0.026
T2 SIR3.137±1.1563.163±1.1863.280±1.2893.689±1.0930.009
Mean ADC (×10−3 mm2/s)1.037±0.2910.912±0.2111.102±0.2970.900±0.1640.000
Tumor diameter (cm)1.200 (0.887–1.762)1.900 (1.325–2.725)1.150 (0.600–2.750)2.550 (1.700–3.750)0.000

Clinical characteristics of patients and MRI morphological features for different molecular subtypes

ParametersLuminal A (n = 52)Luminal B (n = 135)HER2-enriched (n = 31)TN (n = 45)p
ALNM 0.010
 Yes9 (17.3)58 (43.0)12 (38.7)14 (31.1)
 No43 (82.7)77 (57.0)19 (61.3)31 (68.9)
History of hormone use 0.038
 Yes3 (5.8)2 (1.5)3 (9.7)0 (0.0)
 No49 (94.2)133 (98.5)28 (90.3)45 (100.0)
Tumor morphology 0.053
 Mass43 (82.7)114 (84.4)20 (64.5)39 (86.7)
 Non-mass9 (17.3)21 (15.6)11 (35.5)6 (13.3)
Margin 0.206
 Circumscribed21 (40.4)39 (28.9)13 (41.9)19 (42.2)
 Not-circumscribed31 (59.6)96 (71.1)18 (58.1)26 (57.8)
Dynamic curve curve 0.248
 type I8 (15.4)13 (9.6)4 (12.9)7 (15.6)
 type II9 (17.3)30 (22.2)12 (38.7)8 (17.8)
 type III35 (67.3)92 (68.1)15 (48.4)30 (66.7)

ROC analysis of MRI quantitative parameters for separating one subtype from all other subtypes

ParametersAUCCutoff valueSensitivity (%)Specificity (%)p*
Luminal A vs. all others
 T1 SIR0.506≤ 1.27046.15 (40.1, 52.2)61.61 (55.7, 67.5)0.640
 T2 SIR0.550≤ 3.00059.62 (53.7, 65.6)54.50 (48.5, 60.5)0.397
 Mean ADC (×10−3 mm2/s)0.612> 0.98046.15 (40.3, 52.0)70.62 (65.3, 76.0)0.022
 Tumor diameter(cm)0.768≤l.90080.00 (73.1, 86.9)64.2 (57.0, 71.4)0.016
Luminal B vs. all others
 T1 SIR0.510>1.29162.96 (56.2, 69.7)48.44 (41.7, 55.2)0.181
 T2 SIR0.563≤ 3.29865.93 (59.6, 72.3)45.31 (38.6, 52.0)0.169
 Mean ADC (×10−3 mm2/s)0.624≤ 0.97877.78 (71.6, 84.0)44.53 (37.8, 51.3)0.012
 Tumor diameter(cm)0.540>1.55078.63 (71.7, 85.6)35.58 (28.2, 42.9)0.829
HER2-enriched vs. all others
 T1 SIR0.631> 1.50358.06 (50.3, 65.8)69.40 (61.9, 76.9)0.000
 T2 SIR0.517> 2.81567.74 (60.0, 75.5)44.40 (36.6, 52.2)0.927
 Mean ADC (×10−3 mm2/s)0.713> 0.90387.10 (81.5, 92.7)53.02 (45.1, 60.9)0.002
 Tumor diameter(cm)0.543> 2.19060.00 (52.4, 67.6)60.20 (52.6, 67.8)0.697
TN vs. all others
 T1 SIR0.608≤ 1.28664.44 (58.6, 70.2)62.84 (57.0, 68.7)0.176
 T2 SIR0.655>3.15768.89 (61.8, 76.0)59.63 (51.9, 67.4)0.020
 Mean ADC (×10−3 mm2/s)0.562≤ 0.86951.11 (44.1, 58.1)62.39 (54.9, 69.9)0.087
 Tumor diameter(cm)0.706>2.05074.36(65.3, 83.4)57.69 (49.3, 66.1)0.040

Intraclass correlation coefficient (ICC) analysis between the two readers

ParametersICC (95%CI)
T1 SIR0.970 (0.961–0.976)
T2 SIR0.967 (0.957–0.974)
Mean ADC (×10−3 mm2/s) 0.898 (0.871–0.919)
Tumor diameter (cm)0.923 (0.900–0.940)

ROC analysis of combined parameters for separating one subtype from all other subtypes

AUCSensitivity (%)Specificity (%)p
Luminal A vs. all others
 Mean ADC+ tumor diameter0.78182.22 (76.57, 87.87)74.43 (68.99, 79.87)< 0.001
Luminal B vs. all others
 Mean ADC+ALNM0.63962.96 (57.12, 68.80)60.94 (55.04, 66.84)< 0.001
HER2-enriched vs. all others
 T1 SIR + mean ADC+ non-mass0.72838.71(21.56, 55.86)94.4(91.44, 97.36)< 0.001
 TN vs. all others
 T2SIR+ tumor diameter0.72489.74 (85.64, 93.84)52.20 (45.68, 58.72)0.002
DOI: https://doi.org/10.2478/raon-2026-0029 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Submitted on: Jan 23, 2026
Accepted on: Apr 11, 2026
Published on: Jul 4, 2026
In partnership with: Paradigm Publishing Services

© 2026 Yuanping Tao, Hongyan Chao, Yue Ren, Wanjun Zheng, Yuyou Chen, Liang Du, Huanguo Li, Feng Cui, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT